Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

75.95CHF
7:49am EST
Change (% chg)

CHF-0.05 (-0.07%)
Prev Close
CHF76.00
Open
CHF75.90
Day's High
CHF76.35
Day's Low
CHF75.80
Volume
17,540
Avg. Vol
54,147
52-wk High
CHF95.35
52-wk Low
CHF69.85

Chart for

About

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant... (more)

Overall

Beta: 1.37
Market Cap(Mil.): CHF902.19
Shares Outstanding(Mil.): 11.87
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 188.50 15.25
EPS (TTM): -- -- --
ROI: -- -11.67 33.27
ROE: -- -36.21 16.35

BRIEF-Basilea Extends Existing License Agreement With Pfizer For Cresemba

* BASILEA EXTENDS EXISTING LICENSE AGREEMENT WITH PFIZER FOR ANTIFUNGAL CRESEMBA® (ISAVUCONAZOLE) TO CHINA AND ASIA PACIFIC

Dec 01 2017

BRIEF-Basilea Pharmaceutica ‍marketing authorization for Cresemba for Switzerland​

* ‍MARKETING AUTHORIZATION RECEIVED FOR CRESEMBA FOR SWITZERLAND​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Nov 02 2017

BRIEF-Basilea: Marc Engelhardt named new Chief Medical Officer

* BASILEA'S CHIEF MEDICAL OFFICER PROF. ACHIM KAUFHOLD TO RETIRE AND DR. MARC ENGELHARDT NAMED AS SUCCESSOR

Oct 31 2017

BRIEF-Basilea Pharmaceutica says ‍sales of antifungal cresemba in US exceeded threshold

* BASILEA PHARMACEUTICA - ‍SALES OF ANTIFUNGAL CRESEMBA IN US TRIGGER 1ST SALES MILESTONE PAYMENT FROM ASTELLAS PHARMA OF CHF 5 MILLION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Oct 23 2017

BRIEF-Basilea announces license with Shenzhen China Resources Gosun Pharmaceutical Co

* BASILEA ANNOUNCES LICENSE AGREEMENT FOR ANTIBIOTIC ZEVTERA® (CEFTOBIPROLE) WITH SHENZHEN CHINA RESOURCES GOSUN PHARMACEUTICAL CO., LTD. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Sep 28 2017

BRIEF-Cardiome announces agreement with Basilea

* Cardiome announces agreement with Basilea for distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel

Sep 12 2017

BRIEF-Basilea reports significant progress on partnering and development programs

* Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs Source text for Eikon: Further company coverage:

Aug 10 2017

BRIEF-Basilea Pharmaceutica H1 net loss narrows to CHF 20.6 million​

* ‍56 PERCENT INCREASE IN TOTAL H1 REVENUE, AMOUNTING TO CHF 46.2 MILLION​

Aug 10 2017

BRIEF-Basilea completes license agreement with Pfizer for Cresemba

* BASILEA ANNOUNCES COMPLETION OF THE LICENSE AGREEMENT WITH PFIZER FOR ANTIFUNGAL CRESEMBA® FOR EUROPE, RUSSIA, TURKEY AND ISRAEL

Jul 20 2017

BRIEF-Basilea announces license agreement with Pfizer for antifungal Cresemba

* Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey And Israel

Jun 14 2017

Earnings vs. Estimates